Skip to main content

Table 4 Therapies in patients with CHD

From: Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort

 

All patients, n = 23

Group Aa, n = 4

Group B, n = 12

Group C, n = 6

Therapyb,c

 Somatostatin analogue therapy, n (%)

22 (96)

4 (100)

11 (92)

6 (100)

 Chemotherapy, n (%)

5 (22)

0 (0)

1 (8)

4 (67)

 Molecular Therapy, n (%)

6 (26)

0 (0)

4 (33)

2 (33)

 Ablative Therapy, n (%)

2 (9)

0 (0)

2 (17)

0 (0)

 Peptide receptor radionuclide therapy

13 (57)

1 (25)

7 (58)

5 (83)

 Surgery, n (%)

11 (48)

1 (25)

7 (58)

3 (50)

  1. Patient data derived from SwissNET (n = 23)
  2. No significant difference could be detected using Fisher exact test
  3. CHD Carcinoid heart syndrome
  4. aOne patient was excluded from group A as this patient was still alive and the disease is stable
  5. bData were not reported for all patients
  6. cSome patients received multiple therapies
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us